The biopharma became the latest target in the ongoing healthcare M&A bonanza.
News & Analysis: Relypsa
AstraZeneca's pain is Relypsa's gain.
Shares jump in response to an analyst upgrade and positive clinical data, but investors have more pressing concerns ahead.
Rumors that a larger company might attempt to acquire the company sparked investor enthusiasm.
These stocks led the market lower. Find out why.
The company has solidified its balance sheet with a big and expensive debt deal.
Is the biotech still looking to be sold?
New drug approvals on the horizon set the stage for a market share brawl.
A return of M&A rumors ignited a flurry of buying in the company.
Even though the market was down on Thursday, these stocks bucked the downtrend and moved higher. Find out why.